Investing
Eli Lilly Phase 2 Data Shows EloraTZP Outperforms Tirzepatide Alone
By Bear Creek Staff, . Bear Creek Capital Network.
Eli Lilly's combination obesity drug EloraTZP produced an average of 23.3% weight loss in a phase 2 trial, compared to 14.8% for patients on tirzepatide alone, according to The Motley Fool. The trial enrolled patients with both type 2 diabetes and obesity. Lilly plans to move EloraTZP into phase 3 trials in the fourth quarter.
EloraTZP pairs tirzepatide, the active ingredient in Lilly's Mounjaro and Zepbound, with eloralintide, described by The Motley Fool as "a selective amylin receptor agonist." Where tirzepatide acts on two hormonal pathways, EloraTZP acts on three, with eloralintide targeting the feeling of satiety and potentially reducing calorie intake. Lilly is also running a separate phase 3 trial of eloralintide on its own for obesity.
The backdrop matters. Mounjaro and Zepbound together generated more than $14 billion in revenue in the most recent quarter, out of Lilly's $23 billion in total quarterly revenue, the report said. Lilly currently holds 60% of the U.S. GLP-1 market, ahead of Novo Nordisk, whose Ozempic and Wegovy were first to market. Analysts, according to the same report, project the overall GLP-1 market will approach $100 billion by the end of the decade.
Competition is building. The report noted that Viking Therapeutics and Pfizer are among the companies advancing weight loss drug candidates, meaning Lilly's current market position is not guaranteed to hold without continued pipeline progress.
The phase 2 result is encouraging, but it is worth being precise about what it establishes and what it does not. A phase 2 trial is designed primarily to assess efficacy signals and safety in a relatively small population; phase 3 trials are larger, longer and the standard regulators use to evaluate approval. EloraTZP has not yet cleared that bar, and the gap between a strong phase 2 readout and a commercial product is where many drug candidates have stalled. No regulatory timeline has been disclosed.
What the data does show is that Lilly is pursuing a portfolio strategy rather than relying on a single molecule. The logic is straightforward: patients vary in how much weight they need to lose, how they respond to different mechanisms and what side-effect profiles they can tolerate. A company that can offer multiple options across that spectrum is better positioned than one that cannot, particularly as the market matures and payers begin to differentiate on clinical outcomes. Whether EloraTZP ultimately clears phase 3 and reaches patients is the question to watch through 2027 and beyond.
Bear Creek Capital Network publishes content for informational and educational purposes only. Nothing in this article constitutes financial, investment, tax or legal advice, or a recommendation to buy or sell any security. Consider your own circumstances and consult a qualified professional before making financial decisions.